NASDAQ · VIVO
Healthcare · Medical - Diagnostics & Research
$2.36
Down-$0.25 (-9.42%)
Updated Oct 31, 2026, 3:53 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · VIVO
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
VIVO closed at $2.36 after 21 trading sessions, down 29.91% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $2.45 | $2.54 | $2.295 | $2.355 | 637.74K |
| Oct 29, 2026 | $2.75 | $2.75 | $2.51 | $2.60 | 407.99K |
| Oct 28, 2026 | $2.66 | $2.83 | $2.625 | $2.82 | 798.27K |
| Oct 27, 2026 | $2.48 | $2.70 | $2.4514 | $2.63 | 324.6K |
| Oct 26, 2026 | $2.44 | $2.5399 | $2.33 | $2.45 | 447.21K |
| Oct 23, 2026 | $2.24 | $2.44 | $2.20 | $2.42 | 562.6K |
| Oct 22, 2026 | $2.09 | $2.32 | $2.00 | $2.28 | 1.46M |
| Oct 21, 2026 | $2.28 | $3.12 | $2.16 | $2.18 | 9.26M |
| Oct 20, 2026 | $2.09 | $2.22 | $2.00 | $2.20 | 237.07K |
| Oct 19, 2026 | $2.21 | $2.2261 | $2.10 | $2.115 | 318.65K |
| Oct 16, 2026 | $2.36 | $2.36 | $2.07 | $2.10 | 705.52K |
| Oct 15, 2026 | $2.19 | $2.38 | $2.105 | $2.355 | 395.63K |
| Oct 14, 2026 | $2.53 | $2.53 | $2.15 | $2.19 | 639.44K |
| Oct 13, 2026 | $2.86 | $2.89 | $2.551 | $2.60 | 835.88K |
| Oct 12, 2026 | $3.08 | $3.25 | $2.87 | $2.96 | 551.91K |
| Oct 9, 2026 | $3.20 | $3.23 | $3.08 | $3.10 | 251.96K |
| Oct 8, 2026 | $3.18 | $3.25 | $3.07 | $3.22 | 423.16K |
| Oct 7, 2026 | $3.25 | $3.275 | $3.149 | $3.25 | 254.55K |
| Oct 6, 2026 | $3.37 | $3.43 | $3.25 | $3.29 | 291.72K |
| Oct 5, 2026 | $3.35 | $3.4022 | $3.30 | $3.36 | 224.74K |
| Oct 2, 2026 | $3.24 | $3.44 | $3.2301 | $3.36 | 580.09K |
The latest Smart Investors Daily articles mentioning VIVO.
Company
Market Activity
Research & News
VIVO research
Company profile and research snapshot.
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | Noble Capital Markets | Outperform | — |
| Jul 8, 2022 | HC Wainwright & Co. | Neutral | — |
| Feb 7, 2022 | HC Wainwright & Co. | Buy | — |
| Nov 15, 2021 | HC Wainwright & Co. | Buy | — |
| Aug 9, 2021 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 21, 2026
VivoPower PLC (NASDAQ:VIVO, FRA:51J) shares surged as much as 40% to $3.10 in early Wednesday trading after the company signed a heads of agreement with Open Innovation AI to develop secure sovereign AI data centers totalling at least 1 gigawatt over three years. Investors appear to be...
Yahoo · Oct 21, 2026
VivoPower PLC (NASDAQ:VIVO, FRA:51J) and Open Innovation AI have signed a definitive heads of agreement to develop secure sovereign AI data centers, targeting at least 1 gigawatt of capacity over the next three years. The partners will focus on the Nordics, mainland Europe, the Gulf...
Yahoo · Oct 21, 2026
Agreement signed at Sheikh Zayed Museum in Abu Dhabi pairs VivoPower’s powered land and data center infrastructure capabilities with Open Innovation AI’s sovereign AI orchestration and security platform. The partners see a sovereign AI opportunity of more than 40GW in Europe alone, across government administration, defense, medical, educational and financial services sovereign cloud and will target at least 1GW of capacity over the next three years, with further demand across the GCC and Asia. V
Yahoo · Oct 12, 2026
VivoPower PLC (NASDAQ:VIVO, FRA:51J), the infrastructure developer, has mobilised construction on the first phase of a 40-megawatt AI data center at its Mo i Rana facility in northern Norway, with site works awarded to local contractor Øijord & Aanes Entreprenørforretning AS, a firm with...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VIVO.
